Updated clinical data from the Phase 1/2 ABILITY-1 Study evaluating MDNA11, an emerging best-in-class IL-2 therapy, as a monotherapy and in combination with pembrolizumab, will be presented by Dr.

About Cidara Therapeutics Cidara Therapeutics is using its proprietary Cloudbreak ® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human ...

A copy of the poster titled “BBO-11818: an orally bioavailable, highly potent and selective noncovalent pan-KRAS (ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical ...

Pheton Holdings Ltd (NASDAQ: PTHL) (the “Company”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced ...

Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at The Company encourages investors and potential investors to consult the ...

The conference call can be accessed using the following information: ...

A live and archived webcast of the event will also be available on the “Investor Relations” section of the Heartflow website at About Heartflow’s Technology and Research Backed by ACC/AHA guidelines ...

Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on November 6, 2025, at 8:30 a.m. ET. To listen to the live or archived audio ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the ...

To participate in this event, dial in approximately 5 to 10 minutes before the start of the conference call.

The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after ...

SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, ...